BellBrook Labs Recap of SLAS 2019 in Washington DC.
Tuesday, 29 January 2019
BellBrook Labs will be exhibiting and have poster presentations at the upcoming SLAS conference. During the meeting, BellBrook will have information available demonstrating a variety of applications for Transcreener HTS tools. Stop by booth #1702 where you can receive your copy of “A Guide to Measuring Drug-Target Residence Times with Biochemical Assays.” We are looking forward
- Published in Company, HTS Assays
No Comments
How Does a Biochemical Kinase Assay Work?
Monday, 10 December 2018
A kinase assay works by simply measuring the activity of the kinase. A kinase is an enzyme that aids in the transfer of a phosphate from ATP to another specific molecule. They regulate many activities in the human body. The measurement is used to test potential drugs to see how they affect kinase activity. An
- Published in HTS Assays
Sensitive Methyltransferase Assay Proves Successful with PRMT4
Thursday, 11 October 2018
Histone methyltransferases (HMTs) play a critical role in many diseases. Dysregulation of histone methylation and the subsequent alterations in epigenetic states can cause gene expression patterns that drive a variety of cancers,[1] endometriosis,[2] osteoporosis,[3] osteoarthritis and rheumatoid arthritis,[4] cardiovascular disease,[5] and autism,[6] to name only a few. In this light, a global assay for HMT
- Published in Epigenetics, HTS Assays
A Guide to Measuring Drug-Target Residence Times with Biochemical Assays
Wednesday, 22 August 2018
Learn How to Determine Drug-Target Residence Times with Biochemical Assays in this Free Guide Drug-target residence time has become a critical component in the discovery of new therapeutics. BellBrook Labs has recently published a guide to help describe the use of a proven “jump-dilution” method along with BellBrook’s Transcreener Assay platform to help streamline efforts
- Published in HTS Assays
Enhancing Checkpoint Blockade Immunotherapy: Sensitizing Tumors with HSP90 Inhibitors
Wednesday, 02 May 2018
Checkpoint blockade is turning heads in the oncology community. This form of immunotherapy, which uses anti-PD-1 or anti-CTLA-4 antibodies to coax the immune system into recognizing and attacking cancer cells, has been a game-changer — but only for some patients. Types of cancer for which checkpoint blockade currently cannot presently be used include gastrointestinal tumors
- Published in Company, HTS Assays
Webinar: Streamline HTS and Lead Discovery with the Transcreener ADP Kinase Assay
Friday, 16 March 2018
Identifying bona fide hits efficiently and effectively is a challenge in any small molecule drug discovery program. Using the appropriate assays for screening and hit-to-lead is an important determinant of success, but choosing from among the myriad types of assays can be a daunting process. ADP detection simplifies discovery, providing a universal approach to targeting
- Published in HTS Assays, Resources